Here’s what you should know.
1. The study will randomly assign 40 patients who are already scheduled for total knee arthroplasty surgery to receive an active device or placebo device.
2. Completion of the study is slated for December 2018.
3. A BioElectronics distributor is managing the study at the New Mazloum Hospital in Tripoli, Lebanon.
4. “This study will help us gain regulatory clearance and allow for marketing as the standard of care following joint replacement surgeries,” said Ian Rawe, PhD, director of clinical research at BioElectronics.
More articles on supply chain:
Medtronic study: CoreValve TAVR system improves quality of life — 7 insights
Medline plans $19.6M investment for Iowa expansion — 6 insights
Envision Healthcare completes $2.1B American Medical Response divesture — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.